Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04631588 · ClinicalTrials.gov registry record · Phase 1
Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines
A Phase 1 study of Facial Fine Lines, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 172
- Enrollment target
- 5
- Study locations
NCT04631588 is a Phase 1 study of Facial Fine Lines that has completed, run by Allergan. The registered enrollment target is 172 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT04631588, a Phase 1 study of Facial Fine Lines, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 172 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main objective of this study is to assess safety and tolerability of Intradermal (ID) BOTOX in participants with facial fine lines.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Botox
Study Locations (5)
Florida
- Skin and Cancer Associates, LLP /ID# 225152 - Miami
New York
- Laser & Skin Surgery Center of New York /ID# 225153 - New York
Tennessee
- Tennessee Clinical Research Center /ID# 225151 - Nashville
Texas
- Austin Institute for Clinical Research /ID# 225154 - Pflugerville
Utah
- Advanced Clinical Research /ID# 225155 - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2021-11-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04631588
The ClinicalTrials.gov registry entry for NCT04631588 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Facial Fine Lines appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04631588 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04631588 about?
NCT04631588 is a clinical study titled "Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines". The main objective of this study is to assess safety and tolerability of Intradermal (ID) BOTOX in participants with facial fine lines.
What is the current status of trial NCT04631588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 172 participants. The study started on 2020-11-16. Estimated completion is 2021-11-03.
What conditions does trial NCT04631588 study?
This clinical trial studies the following conditions: Facial Fine Lines.
What interventions are being tested in trial NCT04631588?
The interventions under investigation include: Placebo (DRUG), Botox (DRUG).
Who is sponsoring clinical trial NCT04631588?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04631588 being conducted?
This trial has 5 study locations across Florida, New York, Tennessee, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.